IL-25 antibodies are immunological tools targeting the IL-17E cytokine, which regulates type-2 immunity and inflammatory responses. These antibodies enable:
IL-25 antibodies significantly reduce pathology in:
Oxazolone-induced colitis: Anti-IL-25 treatment decreased colon ulceration by 62% and suppressed IL-13 production in lamina propria cells (p<0.01) .
Allergic asthma: Preclinical studies show reduced eosinophil infiltration and airway hyperreactivity .
| Pathway Component | Effect of IL-25 Antibody |
|---|---|
| Dendritic Cells | Inhibits IL-23 production → Limits Th17 development |
| Macrophages | Induces IL-13 expression → Modulates Th2 responses |
| NF-κB Signaling | Blocks nuclear translocation → Reduces IL-8 synthesis |
The ABIN1043787 antibody demonstrates:
Batch Consistency: ≤15% variability in ELISA titers across production lots
Functional Validation: 85% inhibition of IL-25-mediated STAT3 phosphorylation at 10 μg/mL
Recent studies utilize IL-25 antibodies for: